On, 11 December 2001 orphan designation (EU/3/01/074) was granted by the European Commission to PPD Global Ltd., United Kingdom, for halofuginone hydrobromide for the treatment of systemic sclerosis.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2019 on request of the Sponsor.
|Disease / condition||
Treatment of systemic sclerosis
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: